Article
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.
Journal of viral hepatitis - 1 Jun 2022
Hua Rui, Kong Fei, Wen Xiaofeng, Xiong Qingfang, Chen Jiayu, Meng Chenxin, Ma Hong, Tan Youwen, Huang Yan, Jiang Yongfang, Guan Yujuan, Mao Xiaorong, Wang Jiefei, Xin Yongning, Gao Hainv, Xu Bin, Li Cheng, Wu Qiong, Zhang Xian, Wang Zhiqiang, Zhao Liwen, Zhang Yuexin, Li Guangming, Niu Junqi
Abstract excerpt
Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection. Our previous studies indicated that alfosbuvir monotherapy was well-tolerated and druggable in healthy subjects and HCV-infected patients. Here, we evaluate the efficacy and safety of alfosbuvir in combination with daclatasvir in Chinese patients with HCV genotype 1, 2, 3 or 6. In this open-label...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.